Quantcast

DelMar’s cancer treatment show clinical activity against a range of cancers

DelMar Pharmaceuticals said Tuesday that 17 of the first 20 enrolled patients have received at least their first assessment, and nine have been assessed as having achieved a complete response (CR) (9/17, or 53%), seven have been assessed with stable disease (SD), (7/17, or 41%), while nine has been assessed as disease progression (PD) (1/17, or 6%).

Read more